BRKR Stock Down -30% after 7-Day Loss Streak
Bruker (BRKR) stock hit day 7 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -30% return. The company has lost about $1.4 Bil in value over the last 7 days, with its current market capitalization at about $4.6 Bil. The stock remains 47.6% below its value at the end of 2024. This compares with year-to-date returns of 7.9% for the S&P 500.
BRKR develops and manufactures scientific instruments and analytical solutions globally, operating through Life Science, NANO, and Energy & Supercon Technologies segments. Is this drop a warning sign or a setup for rebound? Deep dive with Buy or Sell BRKR.
Comparing BRKR Stock Returns With The S&P 500
The following table summarizes the return for BRKR stock vs. the S&P 500 index over different periods, including the current streak:
- The Next Big Rally in Ford Motor Stock Could Start Like This
- The Risk Factors to Watch Out For in NVIDIA Stock
- Intuitive Surgical Stock Now 16% Cheaper, Time To Buy
- AT&T Stock Pays Out $85 Bil – Investors Take Note
- Intel Stock Pays Out $92 Bil – Investors Take Note
- Comcast Stock Capital Return Hits $44 Bil
| Return Period | BRKR | S&P 500 |
|---|---|---|
| 1D | -4.4% | 0.7% |
| 7D (Current Streak) | -30.2% | -0.7% |
| 1M (21D) | -27.6% | 1.9% |
| 3M (63D) | -22.2% | 13.2% |
| YTD 2025 | -47.6% | 7.9% |
| 2024 | -20.0% | 23.3% |
| 2023 | 7.8% | 24.2% |
| 2022 | -18.3% | -19.4% |
What is the point? Sustained weakness can be more than noise. It often signals shifting sentiment or deeper concerns. A multi-day losing streak may warn of further downside, or present an opportunity to buy if fundamentals are intact. Take a look at what history tells you about whether past dips like this have been buying opportunities or traps: BRKR Dip Buyer Analysis.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 86 S&P constituents with 3 days or more of consecutive gains and 15 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 65 | 7 |
| 4D | 17 | 2 |
| 5D | 4 | 1 |
| 6D | 0 | 4 |
| 7D or more | 0 | 1 |
| Total >=3 D | 86 | 15 |
Key Financials for Bruker (BRKR)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $3.0 Bil | $3.4 Bil |
| Operating Income | $489.1 Mil | $379.2 Mil |
| Net Income | $427.2 Mil | $113.1 Mil |
Last 2 Fiscal Quarters:
| Metric | 2024 FQ4 | 2025 FQ1 |
|---|---|---|
| Revenues | $979.6 Mil | $801.4 Mil |
| Operating Income | $157.0 Mil | $65.7 Mil |
| Net Income | $13.7 Mil | $17.4 Mil |
The losing streak BRKR stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.